Key Takeaways
- Trump administration secures $19.6 billion in commitments from pharmaceutical companies to reshore manufacturing to the U.S. as part of new drug-pricing deals.
- FTC and 22 states sue Amazon (AMZN) for allegedly inflating digital advertising prices through secret surcharges, seeking billions in restitution.
- BridgeBio Pharma (BBIO) enters a voluntary agreement with the U.S. government to expand Medicaid and Medicare access to its drug Attruby without future pricing mandates.
- President Trump signals limited strikes on Iran while reporting that the Strait of Hormuz remains in "extremely good shape" with roughly 30 ships transiting nightly under Navy assistance.
- Federal Reserve Chair Kevin Warsh faces continued pressure from Trump to lower interest rates, though Warsh maintains that current rates remain necessary to combat inflation.
Trump Administration Announces Major Pharma Reshoring and Pricing Deals
U.S. Health Secretary Kennedy announced today that new drug-pricing agreements with nine pharmaceutical firms include $19.6 billion in commitments to reshore production to the United States. These deals are designed to simultaneously lower drug costs for American consumers and strengthen domestic pharmaceutical supply chains by reducing reliance on foreign manufacturing.
The nine companies involved in this latest round include Alcon, Astellas Pharma, BeOne Medicines, BridgeBio Pharma (BBIO), CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals (TEVA), and UCB. These agreements bring the total number of manufacturers participating in the "Most Favored Nation" (MFN) pricing model to 26, now covering approximately 89% of the branded drug market.
FTC Sues Amazon Over Alleged Ad Price Manipulation
The Federal Trade Commission (FTC), joined by 22 state attorneys general, filed a major lawsuit against Amazon (AMZN) alleging the company used a secret "ad surcharge" scheme to inflate prices for over seven years. The complaint claims Amazon manipulated its digital advertising auctions, extracting tens of billions of dollars from more than one million brands and sellers.
Amazon (AMZN) has pushed back strongly, calling the lawsuit "patently false" and arguing that the FTC has provided no evidence of higher consumer prices. The company stated that its pricing approach contradicts claims of consumer harm and that the FTC fundamentally misunderstands how advertisers operate in real-world performance-based auctions.
BridgeBio Expands Access to Attruby
BridgeBio Pharma (BBIO) confirmed it has reached a voluntary agreement with the U.S. government to expand access to its drug Attruby for Medicaid and Medicare Part D patients. Crucially, the company stated the agreement does not include future pricing mandates and will not impact its ForgingBridges copay assistance program, which can reduce out-of-pocket costs to $0 for qualifying patients.
Geopolitical Stability in the Strait of Hormuz
President Trump reported that the Strait of Hormuz is currently in "extremely good shape," with significant oil flow and approximately 30 ships transiting the waterway each night with U.S. Navy assistance. While the President indicated that any potential strikes against Iran would be "limited" in scope, he noted that "we’ll see what happens," citing leadership uncertainty within the Iranian government.
Monetary Policy Tensions Continue
Tensions remain high between the White House and the Federal Reserve as President Trump reiterated his stance that U.S. interest rates are too high. While expressing "a lot of respect" for Fed Chair Kevin Warsh, Trump noted that Warsh "will do what he has to do," even as the central bank maintains a hawkish stance to ensure inflation moves toward its 2% target.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.